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Abstract: P-Glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) in the canalicular
membrane of hepatocytes mediate the biliary excretion of drugs and drug metabolites. To measure
hepatic ABCB1 and ABCG2 activity, we performed positron emission tomography (PET) scans with
the ABCB1/ABCG2 substrate [11C]tariquidar in healthy volunteers and wild-type, Abcb1a/b(−/−),
Abcg2(−/−), and Abcb1a/b(−/−)Abcg2(−/−) mice without and with coadministration of unlabeled
tariquidar. PET data were analyzed with a three-compartment pharmacokinetic model. [11C]Tariquidar
underwent hepatobiliary excretion in both humans and mice, and tariquidar coadministration caused a
significant reduction in the rate constant for the transfer of radioactivity from the liver into bile (by −74%
in humans and by −62% in wild-type mice), suggesting inhibition of canalicular efflux transporter activity.
Radio-thin-layer chromatography analysis revealed that the majority of radioactivity (>87%) in the
mouse liver and bile was composed of unmetabolized [11C]tariquidar. PET data in transporter knockout
mice revealed that both ABCB1 and ABCG2 mediated biliary excretion of [11C]tariquidar. In vitro
experiments indicated that tariquidar is not a substrate of major hepatic basolateral uptake transporters
(SLCO1B1, SLCO1B3, SLCO2B1, SLC22A1, and SLC22A3). Our data suggest that [11C]tariquidar can
be used to measure hepatic canalicular ABCB1/ABCG2 transport activity without a confounding effect
of uptake transporters.
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P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) in the canalicular 
membrane of hepatocytes mediate the biliary excretion of drugs and drug metabolites. To 
measure hepatic ABCB1 and ABCG2 activity, we performed positron emission tomography 
(PET) scans with the ABCB1/ABCG2 substrate [11C]tariquidar in healthy volunteers and wild-
type, Abcb1a/b(-/-), Abcg2(-/-) and Abcb1a/b(-/-)Abcg2(-/-) mice without and with co-administration 
of unlabeled tariquidar. PET data were analyzed with a 3-compartment pharmacokinetic model. 
[11C]Tariquidar underwent hepatobiliary excretion in both, humans and mice, and tariquidar co-
administration caused a significant reduction in the rate constant for transfer of radioactivity from 
liver into bile (by -74% in humans and by -62% in wild-type mice), suggesting inhibition of 
canalicular efflux transporter activity. Radio-thin-layer chromatography analysis revealed that the 
majority of radioactivity (> 87%) in mouse liver and bile was composed of unmetabolized 
[11C]tariquidar. PET data in transporter knockout mice revealed that both ABCB1 and ABCG2 
mediated biliary excretion of [11C]tariquidar. In vitro experiments indicated that tariquidar is not 
a substrate of major hepatic basolateral uptake transporters (SLCO1B1, SLCO1B3, SLCO2B1, 
SLC22A1 and SLC22A3). Our data suggest that [11C]tariquidar can be used to measure hepatic 
canalicular ABCB1/ABCG2 transport activity without a confounding effect of uptake 
transporters. 
Keywords: [11C]tariquidar, ABCB1, ABCG2, liver, canalicular efflux transporter, positron 
emission tomography, pharmacokinetic modeling
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The liver is the major organ involved in the metabolism and excretion of drugs. Many drugs and 
their metabolites cannot penetrate cell membranes by passive diffusion and their hepatobiliary 
excretion therefore involves an interplay between uptake and efflux transporters expressed in the 
basolateral (sinusoidal, blood-facing) and canalicular (bile-facing) cell membranes of 
hepatocytes.1, 2 Uptake of drugs from blood into hepatocytes is often mediated by basolateral 
transport proteins belonging to the solute carrier (SLC) family, such as organic anion-transporting 
polypeptides (SLCO family) or organic cation transporters (SLC22A family), while excretion 
from hepatocytes into bile is mainly carried out by canalicular ATP-binding cassette (ABC) 
transporters, such as P-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) or 
multidrug resistance-associated protein 2 (ABCC2).1, 2 Accordingly, the classical well-stirred 
hepatic clearance model has been expanded to include drug transporters (extended clearance 
model).1, 3 Alterations in hepatic transporter activities by genetic polymorphisms, drug-drug 
interactions (DDIs) or disease-associated mechanisms can lead to pharmacokinetic variability of 
transported drugs affecting their safety and efficacy.4-6 
For an improved mechanistic understanding of the influence of transporters on hepatic drug 
clearance it is helpful not only to consider plasma concentrations, but also drug tissue 
concentrations.7 Positron emission tomography (PET) allows for a non-invasive measurement of 
the tissue pharmacokinetics of radiolabeled drugs and has been applied to assess the activity of 
hepatic transporters,8, 9 using radiotracers such as [11C]dehydropravastatin,10 [11C]rosuvastatin,11, 
12 [11C]metformin,13 15R-[11C]TIC-Me,14 [11C]cholylsarcosine,15 and [11C]erlotinib.16, 17 Although 
most of these radiotracers are also transported by efflux transporters in the canalicular membrane 
of hepatocytes, they have been primarily used to assess the activity of hepatic uptake transporters. 
Measuring the activity of canalicular efflux transporters is less straightforward than for uptake 
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transporters, as it requires knowledge of the concentrations of a probe substrate in hepatocytes 
and in excreted bile. 
Tariquidar is a non-marketed, third-generation ABCB1 inhibitor, which has been investigated in 
clinical studies for its potential to overcome ABCB1-mediated multidrug resistance of tumors.18 
In microdoses as used for PET imaging, tariquidar was shown to be a substrate of murine and 
human ABCB1 and ABCG2, undergoing only negligible metabolism over the short duration of a 
PET scan.19-21 The main route of elimination of tariquidar is hepatobiliary excretion, while 
urinary excretion represents only a minor route.22, 23 PET with [11C]tariquidar has been used to 
visualize ABCB1 and ABCG2 transport activity at the mouse and human blood-brain barrier 
(BBB).19, 20, 24 We hypothesized that [11C]tariquidar might be a useful probe substrate to measure 
the activity of ABCB1 and ABCG2 in the canalicular membrane of hepatocytes. 
In this study, we performed [11C]tariquidar PET imaging in healthy human volunteers and wild-
type or transporter knockout mice without and with unlabeled tariquidar co-administration to 
assess the influence of ABCB1 and ABCG2 on the hepatobiliary excretion of [11C]tariquidar. 
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This study was conducted as a pilot study, registered with EUDRACT (number 2012-005796-
14), approved by the Ethics Committee of the Medical University of Vienna, and conducted in 
accordance with the current version of the Declaration of Helsinki. All subjects gave their written 
consent before the screening examination. Study participants were defined as healthy based on 
medical history, physical examination, routine blood and urine laboratory testing (see Supporting 
Information, Table S1), and were required to be free of any medication for at least 14 days before 
the PET study day.
Genotyping
Venous blood samples (4 mL) were drawn from all study participants and subjects were 
genotyped for the ABCG2 c.421C>A single-nucleotide polymorphism (SNP) as described 
previously.19 
Radiotracer synthesis
A new batch of [11C]tariquidar was synthesized for each administration and formulated in sterile 
0.9% (w/v) aqueous saline solution/ethanol (9/1, v/v) containing 0.7% (v/v) polysorbate-80. For 
intravenous (i.v.) injection into humans an aliquot of the formulated radiotracer solution was 
diluted with physiological saline solution to a final volume of 10 mL.19 Molar activity at the time 
of injection was 37 ± 13 GBq/µmol (n = 11 batches) and radiochemical purity was 98.7 ± 0.9%. 
For preclinical imaging, [11C]tariquidar was formulated in a mixture of 0.9% aqueous 
saline/ethanol/polyethylene glycol 300 (50/15/35, v/v/v) as reported elsewhere.20 Molar activity 
at the time of injection was > 100 GBq/µmol and radiochemical purity was > 98%.
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Five male healthy volunteers (mean age: 30 ± 6 years, mean weight: 81 ± 14 kg) with unknown 
c.421C>A genotype at the time of enrollment and one female subject with the c.421AA genotype 
(60 years, 80 kg) were included into the study. Subjects underwent two consecutive dynamic 60-
minute [11C]tariquidar PET scans of the upper abdominal region on an Advance scanner (General 
Electric Medical Systems, Milwaukee, WI, USA). A first baseline scan was followed by a second 
scan with concurrent i.v. infusion of unlabeled tariquidar. At the start of each PET scan, a 
microdose of [11C]tariquidar was injected as an i.v. bolus over 20 seconds (349 ± 22 MBq, 
corresponding to 9 ± 3 µg of unlabeled tariquidar). In parallel to PET imaging, serial blood 
samples were rapidly drawn every 5-7 seconds from the radial artery for the first 2.5 minutes, 
followed by samples taken at 3.5, 5, 10, 20, 30, 40 and 60 minutes after radiotracer injection. The 
second PET scan was started approximately 2 hours after the end of the baseline scan. One hour 
before start of the second PET scan, an i.v. infusion of unlabeled tariquidar (225 mg free 
base/hour, AzaTrius Pharmaceuticals, Mumbai, India) was started and maintained until the end of 
the second PET scan.19 Three arterial blood samples (4 mL) were collected at the beginning, in 
the middle, and at the end of the second PET scan to measure plasma concentrations of tariquidar 
as described previously.25 For the subject with the c.421AA genotype only the baseline PET scan 
was performed.
Blood and metabolite analysis
Aliquots of blood and plasma were measured for radioactivity in a gamma-counter, which was 
cross-calibrated with the PET camera. Selected plasma samples were analyzed for radiolabeled 
metabolites of [11C]tariquidar using a previously described solid-phase extraction procedure.21 
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Due to the low percentage of radiolabeled metabolites in plasma, total radioactivity counts in 
arterial blood were considered as an input function for PET data analysis. 
Preclinical PET imaging
Female wild-type (n = 5), Abcb1a/b(-/-) (n = 4), Abcg2(-/-) (n = 4), and Abcb1a/b(-/-)Abcg2(-/-) (n = 5) 
mice with a FVB (Friend Leukemia Virus, strain B) genetic background (Taconic Inc., 
Germantown, NY, USA) underwent under isoflurane/oxygen anesthesia two consecutive 60-
minute dynamic PET scans with [11C]tariquidar (32 ± 9 MBq corresponding to < 1 µg of 
unlabeled tariquidar) as described previously.20 At 2 hours before the start of the second scan, 
animals received an i.v. bolus injection of unlabeled tariquidar (15 mg/kg). 
Assessment of radiolabeled metabolites of [11C]tariquidar in mice
The study was approved by the national authorities (Amt der Niederösterreichischen 
Landesregierung) and study procedures were in accordance with the European Communities 
Council Directive of 22 September, 2010 (2010/63/EU). Female FVB mice (Charles River 
Laboratories, Sulzfeld, Germany) weighing 24.0 ± 0.8 g (n =4) were injected under 
isoflurane/oxygen anesthesia via the tail vein with [11C]tariquidar (36 ± 4 MBq in a volume of 
100 µL, formulated in 0.9% (w/v ) aq. saline containing 0.1% (v/v) polysorbate-80). After a 
period of 30 minutes, a terminal blood sample was collected from the retro-bulbar plexus and 
animals were killed by cervical dislocation while under deep anesthesia. Liver, kidneys and gall 
bladder were removed and urine was collected. Blood was centrifuged to obtain plasma, 
unlabeled tariquidar (2.5 mg/mL in 2.5% glucose, 3 µL per 20 µL plasma) was added and 
proteins were precipitated by the addition of acetonitrile (1 µL per µL plasma). To the 
homogenized liver and kidney tissue, unlabeled tariquidar (2.5 mg/mL in 2.5% glucose, 3 µL per 
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organ) was added and proteins were precipitated by the addition of acetonitrile (800 µL for the 
liver, 400 µL for both kidneys). Urine and bile were precipitated by the addition of acetonitrile (1 
µL per µL urine, 2 µL per µL bile). All solutions were vortexed and then centrifuged (12,000 g, 1 
min, 21°C). Each supernatant (plasma, liver, bile, kidneys, urine, 5 µL each) and diluted 
radiotracer solution as reference were spotted on thin-layer chromatography (TLC) plates (silica 
gel 60F 254 nm, 10 × 20 cm; Merck, Darmstadt, Germany) and plates were developed in ethyl 
acetate/ethanol (6/4, v/v). Detection was performed by placing the TLC plates on multisensitive 
phosphor screens (Perkin-Elmer Life Sciences, Waltham, MA). The screens were scanned at 300 
dpi resolution using a PerkinElmer Cyclone® Plus Phosphor Imager (Perkin-Elmer Life 
Sciences).
Imaging data analysis
For the clinical PET data, regions of interest for liver, combined extrahepatic bile duct and gall 
bladder (eBD/GB) and left renal cortex were manually delineated on individual magnetic 
resonance imaging (MRI) data (T1-and T2-weighted MAGNETOM Skyra 3.0T MRI, Siemens 
Medical Solutions, Erlangen, Germany) co-registered to PET images using PMOD 3.6 (PMOD 
Technologies, Zurich, Switzerland). Radioactivity in eBD/GB was assumed to represent the 
radioactivity excreted from liver into bile. For the mouse PET data, the left ventricle of the heart 
(image-derived arterial blood curve), liver, gall bladder, duodenum, intestine and left kidney were 
manually outlined with the medical image data examiner software AMIDE.26 It was assumed that 
the sum of radioactivity in the gall bladder, duodenum and intestine represented the total 
radioactivity in the bile excreted from the liver. Time-activity curves (TACs) obtained from the 
dynamic PET data were normalized to injected dose per body weight and expressed in units of 
standardized uptake value (SUV = (radioactivity per g/injected radioactivity) × body weight) for 
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both clinical and preclinical imaging data sets. From these TACs, the area under the curve (AUC, 
SUV × min) was calculated using Prism 7.0 (GraphPad Software, La Jolla, CA, USA).
A previously developed 3-compartment model 27 was implemented to estimate the rate constants 
defining the transfer of radioactivity between blood and liver (k1 and k2, min-1) and from liver to 
excreted bile (k3, min-1) (see Supporting Information, Figure S1). The radioactivity amount in the 
liver compartment was corrected for the amount of radioactivity in the fraction of blood in the 
liver.27 This model accounts for hepatic tracer delivery via the portal vein and the hepatic artery 
(dual input function) and assumes that the measured radioactivity in tissue corresponds to 
unmetabolized [11C]tariquidar. The radioactivity concentration in the portal vein was 
mathematically estimated from the measured arterial blood data and the PET data during the 
modeling process for both clinical and preclinical data sets.27 The concentration in the hepatic 
artery corresponded to either the sampled radial artery blood for the clinical data analysis or the 
image-derived (from the left ventricle of the heart) arterial blood curve for the preclinical data. 
Hepatic uptake (CLH,uptake) and biliary efflux (CLH,bile) clearances were calculated as previously 
reported.27 Goodness-of-fit was evaluated by visual inspection, by residual plots, by Q-Q plots 
and by calculating Akaike’s Information Criterion, assuming a weighting function as described in 
detail elsewhere.27 
In addition, a graphical analysis method called integration-plot analysis10, 14 was used to 
determine the renal uptake clearance (CLR,uptake), which defines the transfer of radioactivity from 
blood into the kidney. For integration plot analysis with the clinical data, the measured arterial 
blood radioactivity concentrations were interpolated to the midpoints of the individual PET time-
frames, while the image-derived arterial blood curve was used for the preclinical data analysis. In 
order to obtain the total amount of radioactivity in the kidney as needed for integration plot 
analysis, the PET-derived radioactivity concentrations in the kidney were multiplied by reference 
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kidney volumes published in the literature (140 mL for humans and 0.17 mL for mice),28 adjusted 
to the body weight of each individual subject. 
In vitro uptake experiments
In vitro uptake experiments were performed at the Austrian Institute of Technology as described 
in detail elsewhere 16 with [11C]tariquidar in human epidermoid carcinoma A431 cells 
overexpressing organic anion-transporting polypeptide 1B1, 1B3 or 2B1 (SLCO1B1, SLCO1B3, 
or SLCO2B1) and in A431 cells transfected with the empty vector, which had been generated as 
described elsewhere.29 SLCO overexpression was confirmed by Western blotting and 
functionality of the SLCOs was verified by [3H]estrone-3-sulfate uptake experiments. A431 cells 
transfected with the empty vector were used as a negative control. All cell lines were cultured in 
Dulbecco’s modified eagle medium supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin. Cells were maintained at 37°C 
in a humidified atmosphere of 95% air and 5% CO2. For the uptake experiments, 5 × 105 cells per 
well were seeded in 24-well tissue culture plates (VWR, Radno, PA, USA) and incubated for 24 
hours. On the day of the experiment, growth medium was aspirated and cells were washed with 
pre-warmed transport buffer (Hank’s balanced salt solution supplemented with 10 mM N-2-
hydroxyethylpiperazine-N-2-ethane sulfonic acid). Then the pre-warmed transport buffer was 
added and cells were incubated. After 30 minutes, the transport buffer was removed and pre-
warmed transport buffer supplemented with 0.002% (v/v) polysorbate-80 and containing 
[11C]tariquidar (~2 MBq per well, approximately 0.05 µM) was added and cells were incubated 
for additional 0.3, 2, 5, 10, 15, 20 and 30 minutes. Cell count was determined on separate 24-well 
tissue culture plates after each experiment. Radiotracer solutions were aspirated following 
incubation and cells were washed twice with ice-cold transport buffer. Cells were detached using 
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trypsin EDTA (0.25%) and transport buffer was added to transfer the cell suspension into tubes, 
which were measured for radioactivity in a gamma-counter. The uptake experiments were 
performed 2 times with 3 technical replicates each and radioactivity in cells was corrected for 
radioactive decay and expressed as percent of applied dose per 106 cells (%AD/1×106 cells). 
In addition, in vitro uptake experiments were performed at the University Hospital Zurich with 
[3H]tariquidar (American Radiolabeled Chemicals Inc., St. Louis, MO, USA) in wild-type human 
embryonic kidney cortex (HEK 293) cells or HEK 293 cells overexpressing organic cation 
transporter 1, 2 or 3 (SLC22A1, SLC22A2, SLC22A3) or organic cation/carnitine transporter 2 
(OCTN2/SLC22A5) or organic cation/ergothioneine transporter 1 (OCTN1/SLC22A4), which 
were generous gifts of Drs. I Tamai and H. Koepsell. Wild-type HEK 293 cells were cultured in 
Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) fetal bovine serum, 100 
units/mL penicillin and 100 µg/mL streptomycin. The characterization and cultivation of stably 
transfected cells was done as previously described.30-32 Briefly, the culture medium for the SLC-
transfected cell lines additionally contained Geneticin (G-418) as selecting agent (400 µg/mL for 
SLC22A1-, SLC22A2- and SLC22A3- and 600 µg/mL for SLC22A4- and SLC22A5-
overexpressing cells). For uptake experiments with [3H]tariquidar, HEK 293 cells were grown on 
Petri dishes coated with poly-D-lysine. 24 hours before the uptake experiment, cells were treated 
with 5 mM sodium butyrate. Before uptake experiments, cells were rinsed three times with 2 mL 
pre-warmed uptake buffer: 116.4 mM NaCl, 5.3 mM KCl, 1.0 mM NaH2PO4, 0.8 mM MgSO4, 
5.5 mM D-glucose and 20 mM HEPS/Trips pH 7.4.33 Uptake was initiated by addition of pre-
warmed uptake buffer containing labeled and unlabeled tariquidar (total concentration: 1 µM). 
Uptake was stopped after an incubation time of 5 minutes at 37°C by aspiration of the 
radiolabeled solution and rinsing the cells 4 times with 2 mL ice-cold uptake buffer. Cells were 
solubilized for at least 30 minutes with 1% Triton X-100 and 500 µL of this suspension were 
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used for radioactivity measurement by liquid scintillation counting.34, 35 The uptake experiments 
were performed 2-4 times with at least 3 technical replicates each and tariquidar uptake in cells 
was expressed as pmol tariquidar per mg protein. 
Statistical analysis
Statistical analysis was performed using Prism 7.0. After confirmation of normal distribution of 
the data using the Shapiro-Wilk normality test, differences in pharmacokinetic parameters 
between scans were assessed using a two-tailed paired t-test. Differences in parameters between 
mouse groups were analyzed by one-way ANOVA followed by a Tukey’s multiple-comparison 
test. To assess correlations, the Pearson correlation coefficient (r) was calculated. The level of 
statistical significance was set to a p value of less than 0.05. All values are given as mean ± 
standard deviation (SD).
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Healthy volunteers underwent two consecutive PET scans with [11C]tariquidar, a first baseline 
scan in which a microdose of tariquidar was injected (< 10 µg) and a second scan with concurrent 
i.v. infusion of unlabeled tariquidar (225 mg/h). Subjects were genotyped for the ABCG2 SNP 
c.421C>A after the clinical part of the study. Our study cohort included four subjects with the 
c.421CC and one subject with the c.421CA genotype. In addition, one subject with known 
c.421AA genotype was included, for whom only the baseline scan was performed for safety 
reasons. 
Adverse events occurring during study participation for which a relationship with tariquidar 
administration could not be excluded were dysgeusia (two subjects), vertigo (two subjects), 
hypotension (two subjects) and phlebitis (one subject). In each subject, tariquidar plasma 
concentrations were relatively constant during the second PET scan with a mean concentration 
across all subjects (average of three determinations at beginning, middle, and end of PET scan) of 
3.0 ± 0.9 µmol/L (see Supporting Information, Figure S2a). 
For the duration of both PET scans, the majority of radioactivity in plasma was composed of 
unmetabolized [11C]tariquidar without significant differences found between the two scans 
(percentage of unchanged [11C]tariquidar in plasma at 40 minutes after radiotracer injection, scan 
1: 92.6 ± 0.9% and scan 2: 94.3± 1.9%). Serial PET images of the abdominal region (Figure 1) 
indicated rapid and high radioactivity uptake in the liver and excretion of radioactivity into the 
gall bladder at later time points of the first scan. In the second scan, radioactivity concentration in 
the liver and the gall bladder was reduced as compared to scan 1. The total amount of 
radioactivity (percentage of the injected dose) in the liver and combined extrahepatic bile duct 
and gall bladder (eBD/GB) at 60 min after radiotracer injection was 27.8 ± 5.3% and 0.8 ± 0.9%, 
respectively, in scan 1 and 26.9 ± 2.1% and 0.1 ± 0.1%, respectively, in scan 2.
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In none of the subjects, emptying of the gall bladder was observed during the PET scan. In Figure 
2, time-activity curves (TACs) for arterial blood, liver, and eBD/GB are shown. AUCblood was 
significantly increased in scan 2 and AUCliver was significantly decreased leading to a significant 
reduction in the AUCliver/AUCblood ratio (see Supporting Information, Table S2). We used a 
previously developed pharmacokinetic model (see Supporting Information, Figure S1)27 to 
estimate the rate constants for transfer of radioactivity from blood into liver (k1), from liver into 
blood (k2) and from liver into excreted bile (k3) (Table 1). The model provided good fits for both 
the liver and eBD/GB PET data (see Supporting Information, Figure S3). Mean parameters 
estimates for both scans are given in Table 1. Changes in outcome parameters between the two 
scans are depicted in Figure 3. k1 values showed a significant decrease in scan 2, k2 was not 
different between the two scans and k3 was significantly decreased in the second scan. There was 
a trend for a correlation between the percentage change in k3 from scan 1 to scan 2 and the mean 
tariquidar plasma concentrations in scan 2, but statistical significance was not reached (see 
Supporting Information, Figure S2b). The subject with the c.421CA genotype had the lowest k3 
reduction in scan 2 among all subjects, but this could not be explained by tariquidar plasma 
concentrations. Moreover, the subjects with the c.421CA and c.421AA genotypes had the lowest 
k3 values in scan 1 among all subjects (Figure 3c). Hepatic uptake clearance (CLH,uptake) was in a 
similar range as the human liver blood flow rate (21 mL/min/kg body weight)28 and showed a 
significant reduction in scan 2 (Table 1). Hepatic biliary efflux clearance (CLH,bile) showed a 
trend for a decrease in scan 2 without reaching statistical significance (p = 0.0507). However, if 
the subject with the c.421CA genotype (for whom tariquidar co-infusion caused only a small 
reduction in the k3 value) was excluded from the analysis, there was a significant decrease (p = 
0.0372) in CLH,bile from scan 1 (0.0231 ± 0.0130 mL/min/kg) to scan 2 (0.0041 ± 0.0037 
mL/min/kg). Radioactivity concentrations in the kidneys were lower as compared to the liver and 
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similar in the two scans (see Supporting Information, Figure S4). Integration plot analysis was 
used to determine the renal uptake clearance (CLR,uptake) which did not significantly differ 
between scans (0.52 ± 0.12 and 0.51 ± 0.14 mL/min/kg in scan 1 and 2, respectively) (see 
Supporting Information, Table S3). 
Furthermore, we studied [11C]tariquidar disposition in wild-type and ABC transporter knockout 
mice (Abcb1a/b(-/-), Abcg2(-/-), and Abcb1a/b(-/-)Abcg2(-/-)) without and with i.v. pre-treatment with 
unlabeled tariquidar. We also analyzed the percentage of unmetabolized [11C]tariquidar in 
different tissues and fluids of wild-type mice at 30 minutes after radiotracer injection. These 
experiments revealed that the majority of radioactivity in plasma (78.3%), liver (92.8%) and bile 
(87.5%) was composed of unmetabolized [11C]tariquidar (Table 2). Serial PET images showed 
that radioactivity was rapidly taken up by the liver (67 ± 7% of the injected dose) and distributed 
at later time points to the gall bladder and intestine in wild-type mice without tariquidar pre-
treatment (Figure 4). In contrast, in tariquidar pre-treated wild-type mice and in Abcb1a/b(-/-
)Abcg2(-/-) mice radioactivity excretion into the gall bladder and intestine was considerably 
reduced or almost absent. The urinary bladder was not visible on the PET images in any of the 
studied mouse groups. The estimated amount of radioactivity excreted into the urine was very 
low (approximately 0.2% of the injected dose in wild-type mice at the end of the PET scan). The 
blood, liver, intestine and kidney TACs for all studied mouse groups are shown in Figure S5 of 
the Supporting Information and AUC values are given in Table S2 of the Supporting Information. 
Pre-treatment with tariquidar resulted in a significant increase in AUCblood in wild-type mice, 
which was of similar magnitude as in humans. In all three knockout mouse strains, AUCblood was 
significantly higher in scan 1 than in wild-type mice. The pharmacokinetic model was applied to 
the mouse PET data and provided comparably good fits as for the human data (see Supporting 
Information, Figure S6). k1 and k2 values did not differ between scans in any of the studied mouse 
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genotypes (Table 3 and Figure 5). Moreover, for the baselines scans, k1 and k2 values were not 
significantly different between wild-type and transporter knockout mice. Like in humans, k3 
showed a significant reduction in scan 2 in wild-type, Abcb1a/b(-/-) and Abcg2(-/-) mice, but was 
unchanged between scans in Abcb1a/b(-/-)Abcg2(-/-) mice (Table 3 and Figure 5). Furthermore, in 
baseline scans k3 was significantly lower in Abcb1a/b(-/-)Abcg2(-/-) mice as compared to wild-type, 
Abcb1a/b(-/-) and Abcg2(-/-) mice. CLH,uptake was in a similar range as the mouse liver blood flow 
rate (90 mL/min/kg)28 and did not significantly change between scans in any of the studied mouse 
strains (Table 3). CLH,bile significantly decreased in scan 2 in all genotypes, except for 
Abcb1a/b(-/-)Abcg2(-/-) mice. The kidney TACs appeared to be similar in scan 1 and scan 2 and 
between different genotypes (see Supporting Information, Figure S5). CLR,uptake did not show 
significant changes between scans, except for Abcb1a/b(-/-) mice, in which CLR,uptake was 
significantly decreased after tariquidar administration (see Supporting Information, Table S3).
In order to identify potential basolateral hepatocyte transporters for the uptake of [11C]tariquidar 
from blood into the liver, we performed in vitro uptake experiments in transporter-overexpressing 
cells. No significant differences in tariquidar uptake were found between SLCO1B1-, 1B3-, and 
2B1-overexpressing and vector control cells (Figure 6a). Furthermore, the uptake of tariquidar 
was not significantly different between wild-type cells and cells overexpressing SLC22A1, 
SLC22A2, SLC22A3 or SLC22A5, but significantly increased in cells overexpressing SLC22A4 
(Figure 6b).
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We performed PET imaging with the dual ABCB1/ABCG2 substrate [11C]tariquidar in humans 
and mice to assess whether the activities of hepatic canalicular ABCB1 and ABCG2 can be 
measured with this radiotracer. We found a marked decrease in the amount of radioactivity 
excreted into bile in both humans and mice when a pharmacological dose of unlabeled tariquidar 
was co-administered with the radiotracer, which suggested inhibition of canalicular efflux 
transport activity. Moreover, PET data in transporter knockout mice suggested that both ABCB1 
and ABCG2 mediated biliary excretion of [11C]tariquidar. Our findings are of relevance, as they 
extend previous PET imaging work of hepatic transporters to an assessment of canalicular efflux 
transporter activity and highlight the utility of pharmacokinetic modeling in measuring hepatic 
transport activity.
Our PET data were modeled using a previously described 3-compartment pharmacokinetic model 
(see Supporting Information, Figure S1).27 The disposition of [11C]tariquidar in the blood 
compartment was not modeled, but the time course of [11C]tariquidar in blood was used as an 
input function to the model as is typically done for kinetic modeling of PET data. Since the liver 
receives dual blood supply via the hepatic artery (~25%) and the portal vein (~75%), the 
employed model considered a mathematically estimated, flow-weighted dual input function.27 
However, our approach to mathematically estimate the portal vein input function will require 
future validation, e.g. by comparison with an image-derived portal vein input function.
According to the investigator’s brochure,23 upon i.v. tariquidar administration in several species 
(rats, monkeys and humans) the drug is mainly excreted in the form of metabolites into feces with 
negligible urinary excretion. In none of the studied species circulating metabolites of tariquidar 
could be detected in plasma,23 indicating that metabolites cannot distribute from liver back into 
blood or that they are rapidly eliminated from the liver. In the present study, metabolite analysis 
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confirmed in both, humans and mice, only a very low amount of radiolabeled metabolites in 
plasma during the time course of the PET scan. Moreover, in mouse liver and bile, only a small 
amount of radiolabeled metabolites of [11C]tariquidar (< 13%) could be detected at 30 minutes 
after radiotracer injection (Table 2). Thus, it was assumed that metabolism in the liver was still 
negligible over the short duration of the PET scan, and therefore, our pharmacokinetic model 
represented the exchange of unmetabolized radiotracer between the different compartments. 
In humans, k1 showed a moderate but significant reduction, when unlabeled tariquidar was co-
infused in scan 2 (Figure 3). Although this reduction in k1 may indicate a partial inhibition of 
basolateral hepatic transporter(s) mediating the uptake of [11C]tariquidar from blood into the 
liver, in vitro experiments proved that major human basolateral hepatic uptake transporters 
(SLCO1B1, SLCO1B3, SLCO2B1, SLC22A1 and SLC22A3) did not transport tariquidar (Figure 
6). On the other hand, SLC22A4-overexpressing cells showed higher tariquidar uptake as 
compared to wild-type cells suggesting that tariquidar is a substrate of SLC22A4. However, 
while this transporter has been shown to be highly expressed in kidney, spleen, heart or fetal 
liver, expression in the adult liver is controversial.31, 33, 36 Thus, there is at present no firm 
evidence for the involvement of basolateral hepatic uptake transporters in the distribution of 
tariquidar from blood into hepatocytes. Therefore, the moderate reduction in k1 observed in scan 
2 may be related to other reasons than inhibition of uptake transporters, such as changes in 
hepatic blood flow caused by administration of unlabeled tariquidar, assuming that k1 is most 
likely blood flow dependent.
The co-administration of unlabeled tariquidar caused a reduction in the radioactivity excreted into 
bile, as reflected by a significant decrease in the k3 parameter (Figures 3 and 5). PET data in 
Abcb1a/b(-/-)Abcg2(-/-) mice, which showed a 2-fold lower k3 value than wild-type mice (Figure 5), 
indicated that both ABCB1 and ABCG2 were involved in the biliary excretion of [11C]tariquidar. 
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However, when only ABCB1A/B or ABCG2 were missing (Abcb1a/b(-/-) mice or Abcg2(-/-) mice) 
no reduction in k3 was observed (Figure 5). A possible explanation for this could be a 
compensatory upregulation of hepatic ABCB1A/B in Abcg2(-/-) mice and of ABCG2 in 
Abcb1a/b(-/-) mice. This is supported by literature data, reporting approximately 2-fold increased 
ABCB1A protein expression in the liver of the same Abcg2(-/-) mouse strain as used in the present 
study relative to wild-type mice.37 Our data thus suggest inhibition of hepatic ABCB1 and 
ABCG2 transport activity by unlabeled tariquidar leading to decreased biliary excretion of 
[11C]tariquidar. The half maximum-inhibitory concentration (IC50) of tariquidar to inhibit its own 
transport was found to be considerably lower for ABCB1 (17.1 nmol/L) than for ABCG2 (310.4 
nmol/L),19 which is in agreement with tariquidar being a more potent inhibitor of ABCB1 than of 
ABCG2. Accordingly, tariquidar could only inhibit ABCB1 and not ABCG2 activity at the 
human BBB when administered using the same i.v. infusion protocol as in the present study.19 
However, while unbound plasma concentrations of tariquidar may not be sufficiently high to 
inhibit ABCG2 at the human BBB, considerably higher concentrations may be achieved in liver 
tissue, resulting in a higher exposure of hepatic ABCG2 to tariquidar. AUCliver/AUCblood of 
[11C]tariquidar was approximately 40 in the second PET scan in humans (see Supporting 
Information, Table S2), which indicates that total liver concentrations of tariquidar were higher 
(approximately 120 µmol/L) than the corresponding plasma concentrations. However, a relation 
of the unbound liver concentration of tariquidar to its in vitro IC50 for ABCG2 inhibition is not 
feasible as the extent of protein binding of tariquidar in the liver is not known. 
Interestingly, data in carriers of the ABCG2 SNP c.421C>A, which was shown to be associated 
with reduced ABCG2 protein abundance in the human liver,38 pointed to reduced biliary 
excretion of [11C]tariquidar as compared with non SNP carriers (Figure 3). However, this 
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preliminary finding needs to be confirmed in future studies with a larger sample size of subjects 
with different c.421C>A genotypes.
The impaired biliary excretion of [11C]tariquidar was reflected by a significant increase in 
AUCblood from scan 1 to scan 2 (see Supporting Information, Table S2). This scenario may be 
related to a scenario of the extended clearance model described by Patilea-Vrana,3 in which, 
when a drug’s passive permeability across the sinusoidal membrane is high, the inhibition of 
canalicular efflux clearance results in an increase in both systemic and liver concentrations of the 
drug. This scenario differs from the one described with other PET tracers (e.g. 
[11C]dehydropravastatin and [11C]rosuvastatin),10, 12 for which sinusoidal uptake clearance is a 
major determinant of hepatic clearance.3 In the present study, increased accumulation of 
radioactivity in the liver was not observed when biliary excretion was impaired and only a 
moderate increase was observed in the blood concentrations. The rise in liver radioactivity 
exposure due to impaired biliary excretion can be expected to be relatively small as biliary 
excretion occurred very slowly, as reflected by the very low rate constant k3 (0.0009 ± 0.0007 
min-1) and the relatively low amount of radioactivity measured in excreted bile at the end of the 
first PET scan (0.8 ± 0.9% of the injected dose). It can be hypothesized that any rise in liver 
radioactivity exposure was masked by the reduction of k1 in scan 2, which was caused by an 
unknown mechanism (e.g. a tariquidar-induced decrease in hepatic blood flow). An additional 
explanation for the lack of pronounced changes in blood pharmacokinetics may be the existence 
of an alternative excretion pathway. Previous data in healthy human volunteers and the present 
data in mice suggest that urinary excretion of radioactivity following i.v. injection of 
[11C]tariquidar is very low. In healthy volunteers, approximately 2% of the injected dose was 
recovered from urine at the end of a 90-minute PET scan,22 while in wild-type mice this amount 
was approximately 0.2%. According to the investigator’s brochure, tariquidar may undergo direct 
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secretion from blood into the intestine through the gastrointestinal tract mucosa.23 This may 
represent an alternative excretion pathway of tariquidar, which may come into play when biliary 
excretion is impaired. This is also supported by whole body distribution data of [11C]tariquidar in 
healthy human volunteers, who showed moderate intestinal radioactivity uptake.22 Our employed 
PET analysis was not capable of quantifying intestinal secretion of radioactivity, as the intestine 
was not within the field of view of the PET scanner in humans. In mice, on the other hand, the 
radioactivity signal in the intestine could be measured as the entire animal was within the field of 
view of the PET scanner, but we were not able to distinguish intestinal radioactivity arising from 
biliary excretion from intestinal radioactivity arising from direct secretion from blood. 
In conclusion, our data suggest that [11C]tariquidar can be used as a PET probe substrate to 
quantify ABCB1/ABCG2 transport activity in the liver. An advantage of [11C]tariquidar over 
other previously reported PET tracers is its presumably good metabolic stability and the apparent 
lack of an involvement of hepatic uptake transporters, suggesting that canalicular efflux 
transporter activity can be measured without a possible confounding effect of uptake transporters. 
[11C]Tariquidar may find use to assess the effect of DDIs, genetic polymorphisms and disease on 
hepatic transporter activity. Moreover, our data indicate that tariquidar in pharmacological doses 
can inhibit hepatic ABCB1 and ABCG2 transport activity, which may decrease hepatobiliary 
excretion of other ABCB1 and/or ABCG2 substrate drugs and qualify tariquidar as a prototypical 
hepatic ABCB1/ABCG2 inhibitor for DDI studies. 
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Supporting Information
Pharmacokinetic model to describe the hepatobiliary distribution of [11C]tariquidar. Tariquidar 
plasma concentrations during scan 2 and correlation with % change in k3. Model fits in one 
representative subject. TACs in the human kidney cortex. TACs in arterial blood, liver, intestine 
and kidney for wild-type and transporter knockout mice. Model fits for mouse data. Table with 
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human and mouse data. Table with renal uptake clearance values for humans and mice. This 
material is available free of charge via the Internet at http://pubs.acs.org.
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Figure 1. Serial PET images of the abdominal region for baseline scan (scan 1) and scan with 
concurrent infusion of unlabeled tariquidar (scan 2) recorded at different time intervals after 
radiotracer injection. Radioactivity concentration is expressed as standardized uptake value 
(SUV). Anatomical structures are labeled with arrows (L: liver, GB: gall bladder).
Figure 2. Mean time-activity curves (SUV ± SD, n = 5, c.421AA subject for whom only scan 1 
data are available is not included) for arterial blood (a), liver (b), and extrahepatic bile duct and 
gall bladder (eBD/GB, c) for baseline scan (scan 1) and scan with concurrent infusion of 
unlabeled tariquidar (scan 2).
Figure 3. Changes in outcome parameters between the first and second scans for [11C]tariquidar 
hepatobiliary distribution in individual subjects. The rate constants for radioactivity transfer 
between blood and liver (k1 and k2, min-1) are shown in (a) and (b). The rate constant defining the 
transfer of [11C]tariquidar from liver to extrahepatic bile duct and gall bladder (k3, min-1) is 
shown in (c). Insert in (c) shows amplification of lower value data points. Different symbols are 
used according to c.421C>A genotype (c.421CC, n =4, black circles, c.421CA, n = 1, green 
triangle, c.421AA, n = 1, red diamond, only scan 1 data available). * p < 0.05, 2-sided paired t-
test.
Figure 4. Serial PET images of wild-type mice for baseline scan (scan 1) and scan after pre-
treatment with unlabeled tariquidar (scan 2) and for Abcb1a/b(-/-)Abcg2(-/-) mice (baseline scan) 
recorded at different time intervals after radiotracer injection. Radioactivity concentration is 
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expressed as standardized uptake value (SUV). Anatomical structures are labeled with arrows (L: 
liver, GB: gall bladder, D: duodenum, I: intestine).
Figure 5. Outcome parameters for [11C]tariquidar hepatobiliary distribution in different mouse 
genotypes for the baseline scan (scan 1) and scan after pre-treatment with unlabeled tariquidar 
(scan 2). In (a) and (b) the rate constants defining the transfer between blood and liver (k1 and k2, 
min-1) are shown, while the rate constant for transfer from liver to excreted bile (k3, min-1) is 
shown in (c). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA 
followed by a Tukey’s multiple-comparison test.
Figure 6. (a) Uptake (percent of applied dose per 106 cells, %AD/1×106 cells) of tariquidar at 
0.3, 2, 5, 10, 15, 20 and 30 minutes incubation time in A431 cells transfected with empty vector 
(vector control, VC) or A431 cells overexpressing SLCO1B1, SLCO1B3 or SLCO2B1. (b) 
Uptake (pmol/mg protein) of tariquidar at 0 minutes and after 5 minutes incubation time in wild-
type (WT) and SLC22A1-, SLC22A2-, SLC22A3-, SLC22A4- and SLC22A5-overexpressing 
HEK 293 cells. Results show the mean ± SD. Results are from 2-4 independent experiments with 
at least 3 technical replicates each. * p < 0.05, one-way ANOVA followed by a Tukey’s multiple-
comparison test against vector control or wild-type for each studied time point.
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Table 1. Pharmacokinetic parameters for baseline scan and scan with concurrent infusion 
of unlabeled tariquidar in humans.
Parameter Baseline scan Tariquidar co-infusion Percentage change
k1 (min-1) 4.81 ± 0.94 (3-16) 4.01 ± 1.01 (3-7)* -17± 13%
k2 (min-1) 0.0022 ± 0.0028 (14-140) 0.0024 ± 0.0020 (13-130) +18± 101%
k3 (min-1) 0.0009 ± 0.0007 (1-3) 0.0002 ± 0.0002 (2-3)* -74± 24%
CLH,uptake (mL/min/kg) 25.11 ± 5.41 20.64 ± 5.99* -18± 13%
CLH,bile (mL/min/kg) 0.0187 ± 0.0149 0.0035 ± 0.0034 -74± 24%
Parameter estimates are given as mean ± SD (n = 5). Values in parentheses represent the range in 
percent coefficient of variation (%CV) of the parameters (parameter precision). Percentage 
change was calculated as the mean of the individual percentage changes from scan 1 to scan 2. * 
p < 0.05, two-tailed paired t-test for comparison with baseline scan. k1 and k2 are the rate 
constants for transfer of radioactivity between liver and blood, and k3 is the rate constant 
describing transfer of radioactivity from liver to extrahepatic bile duct and gall bladder. CLH,uptake 
and CLH,bile are the hepatic uptake and biliary efflux clearances, calculated from k1 and k3, 
respectively: CLH,uptake = (k1 × Vblood)/wbody, and CLH,bile = (k3 × Vliv)/wbody, where Vblood (mL) is 
the volume of blood in the liver (0.25 mL of blood per mL of liver tissue), Vliv (mL) is the 
physiological volume of the liver and wbody is the subject’s body weight. 
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Table 2. Percentage of unchanged [11C]tariquidar in different tissues and 
fluids of female FVB wild-type mice measured at 30 minutes after 
radiotracer injection with radio-TLC.
Animal ID % of unchanged [11C]tariquidar
Plasmaa Plasmaa Liver Bile Kidneys Urine
M150 84.2 78.6 93.3 90.2 96.4 19.9
M151 76.8 71.6 92.9 91.8 95.4 52.7
M152 92.5 70.9 92.6 80.5 93.6 37.7
M153 73.8 77.7 92.4 n.d. 94.2 42.1
Mean ± SD 78.3 ± 6.7 92.8 ± 0.3 87.5 ± 5.0 94.9 ± 1.1 38.1 ± 11.8
n.d.: not determined
a Two technical replicates for plasma
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Table 3. Pharmacokinetic parameters for baseline scan and scan after pre-treatment with 
unlabeled tariquidar in mice.





k1 (min-1) 8.92 ± 1.28 (2-3) 7.72 ± 0.98 (2-3) -12 ± 14%
k2 (min-1) 0.13 ± 0.02 (2-4) 0.15 ± 0.04 (2-3) +18 ± 23%
k3 (min-1) 0.0083 ± 0.0009 (1-2) 0.003 ± 0.001 (1-2)* -62 ± 18%
CLH,uptake (mL/min/kg) 145.20 ± 20.55 125.40 ± 15.88 -13 ± 14%
Wild-type
CLH,bile (mL/min/kg) 0.54 ± 0.06 0.20 ± 0.08* -62 ± 18%
k1 (min-1) 7.67 ± 2.32 (1-3) 8.18 ± 2.46 (2-3) +10 ± 26%
k2 (min-1) 0.15 ± 0.05 (1-3) 0.19 ± 0.06 (2-3) +29 ± 33%
k3 (min-1) 0.0038 ± 0.0005 (1-2)x 0.0031 ± 0.0019 (1-11) -14 ± 56%
CLH,uptake (mL/min/kg) 124.70 ± 37.69 132.90 ± 39.88 +10 ± 26%
Abcb1a/b(-/-)
Abcg2(-/-)
CLH,bile (mL/min/kg) 0.24 ± 0.03xxx 0.20 ± 0.13 -14 ± 56%
k1 (min-1) 7.86 ± 0.19 (2-4) 9.60 ± 2.49 (2-4) +22 ± 32%
k2 (min-1) 0.12 ± 0.02 (2-4) 0.19 ± 0.06 (2-4) +57 ± 55%
k3 (min-1) 0.0083 ± 0.0009 (1-2) 0.0030 ± 0.0012 (2-3)* -62 ± 18%
CLH,uptake (mL/min/kg) 127.7 ± 3.05 156.10 ± 40.37 +22 ± 32%
Abcb1a/b(-/-)
CLH,bile (mL/min/kg) 0.54 ± 0.06 0.20 ± 0.08* -62 ± 18%
k1 (min-1) 7.17 ± 1.58 (2-6) 6.58 ± 2.24 (2-3) -5 ± 37%
k2 (min-1) 0.15 ± 0.04 (2-5) 0.16 ± 0.07 (2-3) +11 ± 51%
k3 (min-1) 0.008 ± 0.001 (1-2) 0.002 ± 0.001 (3-8)** -77 ± 20%
CLH,uptake (mL/min/kg) 116.5 ± 25.68 106.9 ± 36.31 -5 ± 37%
Abcg2(-/-)
CLH,bile (mL/min/kg) 0.49 ± 0.09 0.11 ± 0.09** -77 ± 21%
Each value represents mean ± SD (n = 4-5 per group). Values in parentheses represent the range 
in percent coefficient of variation (%CV) of the parameters (parameter precision). Percentage 
change was calculated as the mean of the individual percentage changes from scan 1 to scan 2. * 
p < 0.05, ** p < 0.01, two-tailed paired t-test for comparison of second scan with baseline scan. x 
p < 0.05, xxx p < 0.001, one-way ANOVA followed by a Tukey’s multiple-comparison test for 
comparison of parameters between wild-type mice and the three knockout strains. k1 and k2 are 
the rate constants for transfer of radioactivity between liver and blood, and k3 is the rate constant 
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describing transfer of radioactivity from the liver to the excreted bile in the intestine. CLH,uptake 
and CLH,bile are the hepatic uptake and biliary efflux clearances, calculated from k1 and k3, 
respectively: CLH,uptake = (k1 × Vblood)/wbody, and CLH,bile = (k3 × Vliv)/wbody, where Vblood (mL) is 
the volume of blood in the liver (0.25 mL of blood per mL of liver tissue), Vliv (mL) is the 
physiological volume of the liver and wbody is the subject’s body weight. 
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